Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10493 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

in response to

Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

narmac

posted on May 17, 2022 11:21AM

narmac, let's hope that Don does not invite Eversana over onto Zenith and muddy up the waters even more. What are you smoking these days?

But I tell you, Zenith looks more promising than RVX right now. Hoping one of the collaborations works out for Zenith.